Lars Fruergaard Jørgensen, Novo Nordisk CEO (Christopher Goodney/Bloomberg via Getty Images)

August 8, 2023 06:52 AM EDTUpdated 11:29 AM

Updated: Novo Nordisk's semaglutide injection reduces cardiovascular events by 20% in vast SELECT trial

Katherine Lewin

News Reporter

Novo Nordisk’s semaglutide injection reduced major adverse cardiovascular events by 20% in obese or overweight patients without diabetes, further bolstering the case for more widespread …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Updated: Novo Nordisk's semaglutide injection reduces cardiovascular events by 20% in vast SELECT trial

Katherine Lewin

News Reporter

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Up­dat­ed: No­vo Nordisk's semaglu­tide in­jec­tion re­duces car­dio­vas­cu­lar events by 20% in vast SE­LECT tri­al

News Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Updated: Novo Nordisk's semaglutide injection reduces cardiovascular events by 20% in vast SELECT trial